Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

被引：0

作者：

De Gramont, A. ^{[1
]}

Henriques, J. ^{[2
]}

Baruch, B. ^{[3
,4
]}

Kim, T. W. ^{[5
]}

Martinez-Villacampa, M. ^{[6
]}

Gallego-Plazas, J. ^{[7
]}

Cervantes, A. ^{[8
]}

Shim, K. ^{[9
]}

Jonker, D. J. ^{[10
]}

Guerin-Meyer, V. ^{[11
]}

Mineur, L. ^{[12
]}

Banzi, M. ^{[13
]}

Dewdney, A. ^{[14
]}

Dejthevaporn, T. Sirisingha ^{[15
]}

Bloemendal, H. J. ^{[16
]}

Roth, A. D. ^{[17
]}

Thompson, P. ^{[18
]}

Moehler, M. ^{[19
]}

Aranda Aguilar, E. ^{[20
]}

Andre, T. ^{[21
]}

机构：

[1] Inst Hosp Franco Britannique, Dept Med Oncol, Levallois Perret, France

[2] Univ Hosp Besancon, INSERM, UMR 1098, Methodol & Qual Life Unit Oncol, Besancon, France

[3] Rabin Med Ctr, Davidoff Canc Ctr, Dept Oncol, Petah Tiqwa, Israel

[4] Sackler Sch Med, Tel Aviv, Israel

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[6] Inst Catala Oncol IDIBELL Hospitalet, Dept Med Oncol, Barcelona, Spain

[7] Gen Univ Elche Hosp, Dept Med Oncol, Elche, Spain

[8] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[9] Lakeridge Hlth RS McLaughlin Durham Reg Canc Ctr, Med Oncol, Oshawa, ON, Canada

[10] Univ Ottawa, Ottawa Hosp Res Inst, Div Med Oncol, Dept Med, Ottawa, ON, Canada

[11] Inst Cancerol Ouest Paul Papin, Dept Gastroenterol & Hepatol, Angers, France

[12] Inst St Catherine, Radiotherapy & Oncol GI & Liver, Avignon, France

[13] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, Oncol Unit, Reggio Emilia, Italy

[14] Weston Pk Hosp, Canc Res Ctr, Dept Oncol, Sheffield, S Yorkshire, England

[15] Ramathibodi Hosp, Med Oncol, Bangkok, Thailand

[16] Meander Med Ctr, Dept Internal Med Med Oncol, Amersfoort, Netherlands

[17] HUG, Dept Oncol, Digest Tumour Unit, Geneva, Switzerland

[18] Auckland City Hosp, Dept Med Oncol, Auckland, New Zealand

[19] Univ Med Mainz, Dept Med Oncol, Mainz, Germany

[20] Univ Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain

[21] Hop St Antoine, Dept Med Oncol, Paris, France

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

553P

引用

页数：1

共 50 条

[31] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
Grothey, A.
Sobrero, A.
Meyerhardt, J. A.
Yoshino, T.
Paul, J.
Taieb, J.
Souglakos, I.
Kerr, R.
Labianca, R.
Shields, A. F.
Bonnetain, F.
Yamanaka, T.
Boukovinas, I.
Shi, Q.
Meyers, J. P.
Niedzwiecki, D.
Torri, V.
Sargent, D. J.
Andre, T.
Iveson, T.
ANNALS OF ONCOLOGY, 2017, 28
[32] A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trial
Hoff, P.
Clarke, S.
Cunningham, D.
Van Cutsem, E.
Moore, M.
Schmoll, H. J.
Tabernero, J.
Mueller, B.
De Gramont, A.
EJC SUPPLEMENTS, 2009, 7 (02): : 324 - 324
[33] An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: compliance and safety of the phase III Japanese ACHIEVE trial
Eto, T.
Kotaka, M.
Manaka, D.
Hasegawa, J.
Takagane, A.
Nakamura, M.
Kato, T.
Munemoto, Y.
Nakamura, F.
Bando, H.
Taniguchi, H.
Gamoh, M.
Shiozawa, M.
Yamanaka, T.
Mizushima, T.
Sakamoto, J.
Saji, S.
Mori, M.
Ohtsu, A.
Yoshino, T.
ANNALS OF ONCOLOGY, 2016, 27 : 121 - 121
[34] Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
Kumamoto, Kensuke
Nakachi, Yutaka
Mizuno, Yosuke
Yokoyama, Masaru
Ishibashi, Keiichiro
Kosugi, Chihiro
Koda, Keiji
Kobayashi, Michiya
Tanakaya, Kohji
Matsunami, Toshio
Eguchi, Hidetaka
Okazaki, Yasushi
Ishida, Hideyuki
ONCOLOGY LETTERS, 2019, 18 (02) : 1388 - 1394
[35] Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study
Boyle, Jemma M.
Kuryba, Angela
Cowling, Thomas E.
van der Meulen, Jan
Fearnhead, Nicola S.
Walker, Kate
Braun, Michael S.
Aggarwal, Ajay
INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (02) : 335 - 346
[36] Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC).
Nakamoto, Yoshihiko
Ishiguro, Megumi
Yoshida, Motoki
Ikejiri, Koji
Mochizuki, Izumi
Mochizuki, Hidetaka
Kotake, Kenjiro
Kameoka, Shingo
Takahashi, Keiichi
Watanabe, Toshiaki
Watanabe, Masahiko
Boku, Narikazu
Tomita, Naohiro
Matsubara, Yoshihiro
Sugihara, Kenichi
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[37] Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer
Megumi Ishiguro
Hidetaka Mochizuki
Naohiro Tomita
Yasuhiro Shimada
Keiichi Takahashi
Kenjiro Kotake
Masahiko Watanabe
Yukihide Kanemitsu
Hideki Ueno
Toshiaki Ishikawa
Hiroyuki Uetake
Shigeyuki Matsui
Satoshi Teramukai
Kenichi Sugihara
BMC Cancer, 12
[38] Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer
Ishiguro, Megumi
Mochizuki, Hidetaka
Tomita, Naohiro
Shimada, Yasuhiro
Takahashi, Keiichi
Kotake, Kenjiro
Watanabe, Masahiko
Kanemitsu, Yukihide
Ueno, Hideki
Ishikawa, Toshiaki
Uetake, Hiroyuki
Matsui, Shigeyuki
Teramukai, Satoshi
Sugihara, Kenichi
BMC CANCER, 2012, 12
[39] An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial.
Eto, Tetsuya
Kotaka, Masahito
Manaka, Dai
Hasegawa, Junichi
Takagane, Akinori
Nakamura, Masato
Kato, Takeshi
Munemoto, Yoshinori
Nakamura, Fumitaka
Bandou, Hiroyuki
Taniguchi, Hiroki
Gamoh, Makio
Shiozawa, Manabu
Yamanaka, Takeharu
Mizushima, Tsunekazu
Sakamoto, Junichi
Saji, Shigetoyo
Mori, Masaki
Ohtsu, Atsushi
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer: YCOG1402 (SOAP trial)
Suwa, Yusuke
Watanabe, Jun
Suwa, Hirokazu
Ozawa, Mayumi
Momiyama, Masashi
Ishibe, Atsushi
Nagamine, Kotaro
Yamagishi, Shigeru
Ota, Mitsuyoshi
Fukushima, Tadao
Sekido, Hitoshi
Saigusa, Yusuke
Endo, Itaru
ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (06): : 922 - 931

← 1 2 3 4 5 →